Posted by Michael Wonder on 03 Mar 2020
MeiraGTx announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product designations granted by the EMA to AAV-RPGR gene therapy for the treatment of X-linked retinitis pigmentosa
2 March 2020 - PRIME designation granted based on clinical data from ongoing Phase 1/2 trial of AAV-RPGR.
MeiraGTx today announced that the EMA has granted Priority Medicines (PRIME) and Advanced Therapy Medicinal Product designations to AAV-RPGR, MeiraGTx’s investigational gene therapy for the treatment of x-linked retinitis pigmentosa caused by mutations in the RPGR gene.
MeiraGTx and Janssen are jointly developing AAV-RPGR as part of a broader collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases.
